Literature DB >> 12563278

In situ assembly of enzyme inhibitors using extended tethering.

Daniel A Erlanson1, Joni W Lam, Christian Wiesmann, Tinh N Luong, Robert L Simmons, Warren L DeLano, Ingrid C Choong, Matthew T Burdett, W Michael Flanagan, Dennis Lee, Eric M Gordon, Tom O'Brien.   

Abstract

Cysteine aspartyl protease-3 (caspase-3) is a mediator of apoptosis and a therapeutic target for a wide range of diseases. Using a dynamic combinatorial technology, 'extended tethering', we identified unique nonpeptidic inhibitors for this enzyme. Extended tethering allowed the identification of ligands that bind to discrete regions of caspase-3 and also helped direct the assembly of these ligands into small-molecule inhibitors. We first designed a small-molecule 'extender' that irreversibly alkylates the cysteine residue of caspase-3 and also contains a thiol group. The modified protein was then screened against a library of disulfide-containing small-molecule fragments. Mass-spectrometry was used to identify ligands that bind noncovalently to the protein and that also form a disulfide linkage with the extender. Linking the selected fragments with binding elements from the extenders generates reversible, tight-binding molecules that are druglike and distinct from known inhibitors. One molecule derived from this approach inhibited apoptosis in cells.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12563278     DOI: 10.1038/nbt786

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   54.908


  30 in total

Review 1.  Molecular targeting of angiogenesis for imaging and therapy.

Authors:  Simon S Brack; Ludger M Dinkelborg; Dario Neri
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-08-05       Impact factor: 9.236

Review 2.  The protein structures that shape caspase activity, specificity, activation and inhibition.

Authors:  Pablo Fuentes-Prior; Guy S Salvesen
Journal:  Biochem J       Date:  2004-12-01       Impact factor: 3.857

3.  Identification of specific tethered inhibitors for caspase-5.

Authors:  Junjun Gao; James A Wells
Journal:  Chem Biol Drug Des       Date:  2011-11-28       Impact factor: 2.817

4.  In silico identification and crystal structure validation of caspase-3 inhibitors without a P1 aspartic acid moiety.

Authors:  Rajkumar Ganesan; Stjepan Jelakovic; Peer R E Mittl; Amedeo Caflisch; Markus G Grütter
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2011-07-13

Review 5.  Small Molecule Active Site Directed Tools for Studying Human Caspases.

Authors:  Marcin Poreba; Aleksandra Szalek; Paulina Kasperkiewicz; Wioletta Rut; Guy S Salvesen; Marcin Drag
Journal:  Chem Rev       Date:  2015-11-09       Impact factor: 60.622

6.  Reversible, allosteric small-molecule inhibitors of regulator of G protein signaling proteins.

Authors:  Levi L Blazer; David L Roman; Alfred Chung; Martha J Larsen; Benjamin M Greedy; Stephen M Husbands; Richard R Neubig
Journal:  Mol Pharmacol       Date:  2010-06-22       Impact factor: 4.436

Review 7.  Emerging principles in protease-based drug discovery.

Authors:  Marcin Drag; Guy S Salvesen
Journal:  Nat Rev Drug Discov       Date:  2010-09       Impact factor: 84.694

8.  Role of loop bundle hydrogen bonds in the maturation and activity of (Pro)caspase-3.

Authors:  Brett Feeney; Cristina Pop; Paul Swartz; Carla Mattos; A Clay Clark
Journal:  Biochemistry       Date:  2006-11-07       Impact factor: 3.162

Review 9.  Targeting Non-Catalytic Cysteine Residues Through Structure-Guided Drug Discovery.

Authors:  Kenneth K Hallenbeck; David M Turner; Adam R Renslo; Michelle R Arkin
Journal:  Curr Top Med Chem       Date:  2017       Impact factor: 3.295

10.  Discovery of an allosteric site in the caspases.

Authors:  Jeanne A Hardy; Joni Lam; Jack T Nguyen; Tom O'Brien; James A Wells
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-16       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.